Gate Bioscience Widens Lilly Deal to Target Hard-to-Drug Proteins
Gate Bioscience has expanded its collaboration with Eli Lilly to develop molecular gate medicines, with potential deal value exceeding $870 million.
Gate Bioscience has broadened its existing collaboration and license agreement with Eli Lilly to pursue therapeutics aimed at proteins long considered beyond the reach of conventional drug design, the company announced. The expanded partnership centers on Gate Bioscience's proprietary molecular gate technology platform, which the company says is engineered to engage targets that have historically resisted standard drug development approaches.
The potential total value of the expanded arrangement exceeds $870 million, according to the announcement, reflecting milestone payments and other consideration that would be triggered as the program advances. Financial terms beyond that headline figure were not disclosed in the release.
Read more HashSmash Contest Pits AI Agents Against Core Crypto Hash Functions →
The agreement builds on an existing relationship between the two companies, signaling Lilly's continued confidence in Gate Bioscience's platform as a mechanism for unlocking a class of disease-relevant proteins that have stymied the broader pharmaceutical industry. Difficult-to-drug proteins represent a significant unmet medical need, as many are implicated in cancer, neurological conditions, and other serious diseases where treatment options remain limited.
For Gate Bioscience, the expansion with a major pharmaceutical partner of Lilly's scale provides both capital runway and validation for its technology at a competitive stage of the biotech landscape. The companies did not specify which protein targets fall under the expanded scope of the deal or offer a projected timeline for clinical development milestones.
Continue reading at GlobeNewswire - Industry News on Financial Services.
